Health Care/Hospital

Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting

SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today presented updated long...

2021-04-10 21:33 2317

HealthyRecipes101.com Offers Free Access to 300 Nutritionist-approved Recipes

SAN FRANCISCO, April 9, 2021 /PRNewswire/ -- Home cooks can now access Healthy Kitchen 101 LLC's collection of nutritionist-approved recipes on its new domain atHealthyRecipes101.com , announced Luna Regina , founder of the compan...

2021-04-09 22:44 1227

Bionomics Successfully Completes A$22.9 million Equity Raise

ADELAIDE, Australia, April 9, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on8 March 2021 (Entitlement Offer) and concurrent placement that was announced on17 March 2021 (Concurr...

2021-04-09 18:00 2691

Control Bionics (ASX:CBL) Partners with Numotion as Northeastern U.S. Reseller of Assistive Technology Solutions

Strategic Partnership Offers Customers More Access to Control Bionics' Industry-Leading Trilogy Product Line MILFORD, Ohio and NEW SOUTH WALES, Australia, April 9, 2021 /PRNewswire/ -- Control Bionics, a global assistive technology company specializing in speech generating devices, announced it ...

2021-04-09 04:16 417

ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting

SHENZHEN, China, April 8, 2021 /PRNewswire/ -- ImmVira today announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting onJune 4-8 2021. Results from the first Phase 1 study of MVR-T3011 as an intr...

2021-04-08 20:47 958

Hyundai Bioscience leads in the repurposing of Niclosamide

SEOUL, South Korea, April 8, 2021 /PRNewswire/ -- A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-reno...

2021-04-08 17:17 867

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S

SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity...

2021-04-07 06:00 4009

MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer

- MitoImmune initiates a Phase 2 trial of oral mucositis (OM) prevention in the first half of 2021 in the US and Korea, and is expanding OM treatment into hematopoietic stem cell transplantation clinical trials SEOUL, South Korea, April 6, 2021 /PRNewswire/ -- MitoIm...

2021-04-06 20:00 2167

Brattea, a Leading Renal Denervation Company in China, Completes over $US20 Million Series B+ Financing, led by Kuanping Capital

SHANGHAI, April 6, 2021 /PRNewswire/ -- Brattea, a leading renal denervation (RDN) medical technology company inChina, announced today its successful completion of over$US20 million Series B+ financing led by healthcare private equity fund Kuanping Capital. New investors include Hengxu Capital, P...

2021-04-06 20:00 39861

US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002

SHANGHAI, April 2, 2021 /PRNewswire/ -- On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial inthe United States. Preclinical data showed that ...

2021-04-02 13:40 3667

Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy

WUHAN and SUZHOU, China, April 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company developing adeno-associated viral (AAV)-delivered gene therapies for the treatment of ocular diseases, recently announced the Center for Drug Evaluation (CDE) of China...

2021-04-01 20:39 4019

Molecular Data Inc. intends to further upgrade its digital tools using Blockchain

SHANGHAI, April 1, 2021 /PRNewswire/ -- Molecular Data Inc. ("Molecular Data" or the "Company") (Nasdaq: MKD), a leading technology-driven platform inChina's chemical industry, announced that it has signed a cooperation agreement with Dalian Lianhua Chemical Co., Ltd. ("Dalian Lianhua"), a leadin...

2021-04-01 19:00 1007

Jolly Good Newly Establishes CBT VR Specialist Department with Clinical Psychiatrists

TOKYO, April 1, 2021 /PRNewswire/ -- Leading Japanese medical VR company Jolly Good Inc. has recently established a specialized DTx Division to develop digital therapeutics (hereinafter "DTx") using VR and AI technologies. Logo: https://kyodonewsprwire.jp/img/202103313079-O1-CAsOT26u

2021-04-01 16:00 274

Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib

* Linperlisib provides significant clinical improvement in the treatment for patients with relapsed and/or refractory follicular lymphoma * Linperlisib has a differentiated and well manageable safety profile SHANGHAI ,March 31, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Y...

2021-04-01 14:09 485

Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.

SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...

2021-03-31 20:45 2157

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...

2021-03-31 20:30 1006

Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enr...

2021-03-31 20:00 8869

AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Market

SHANGHAI, March 31, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, and SIFI S.p.A. ("SIFI"), a leading international ophthalmic com...

2021-03-31 19:30 1243

3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth

SHANGHAI, March 30, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It once again demonst...

2021-03-31 09:11 1882

ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China

* 3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications inGreater China * ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on N...

2021-03-31 09:00 1301
12345 ... 587